inno.N

Preparing our future with R&D

Introduction

inno.N is performing ceaseless research activities to bring up the next generation products with its competitive R&D capacity and experience.

R&D Goals

Disease-
Focus Developing disease-focused & innovative medicines and biologicals
Open
Innovation Accelerating R&D process and bringing positive outputs by open innovation
Distinguished technologies Blockbuster generic products and IMD products development
Platform technologies Exporting technologies/products globally

inno.N R&D Center is expanding research area based on R & D's own research capabilities and platform technology, we are leaping into a global bio-health company by creating visible results. inno.N R&D Center is conducting various research activities with four goals to achieve the mission of 'Heal the World for Better Life'.

inno.N Corp. Osong Plant

R&D achievements

We are leaping into a global bio-health company.

2019
Launched Korea's 30th new drug K-CAB Tab.,
Launched Exone-R Tab., fixed dose combination for hypertension with dyslipidemia
- Amlodipine / Valsartan / Rosuvastatin combination drug
2018
'K-CAB‘Tab.(ingredient name: Tegoprazan),
in-house developed new drug for gastroesophageal reflux disease,
has received a license from the Ministry of Food and Drug Safety
- Korea’s No.30 New Drug
2018

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment)
to NCPC GeneTech in China
2017

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment)
to YL Biologics in Japan
2016
Launched MACHKHAN, fixed dose combination IMD for hypertension
- ARB/CCB combination drug
- First Candesartan / Amlodipine combination drug
2016
New drug for Gastroesophageal acid reflux K-CAB Tab.(Tegoprazan)
- P-CAB (Potassium -Competitive Acid Blocker) New Drug
- Technology export to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (2015)
- New Drug Application (2017)
2014
Launched VOGMET, fixed dose combination IMD for Diabetes
- α-glucosidase/biguanides combination drug
- First Voglibose/Metformin combination drug
2013
Launched EXONE, combination drug for hypertension
- ARB/CCB combination drug
- Valsartan / Amlodipine combination drug
- Excellent optical (light) stability with differentiated technology
2012
Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
- Accredited in ‘Excellence in new drug R & D capability and overseas expansion capability’
1998
Launched EPOKINE, renal anemia treatment
- Developed the first EPO(erythropoietin) in Korea and the third in the world
1995
CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
- Used the first in-vivo substance, TOF, in Korea
1992
Launched CONDITION, a nationwide anti hangover drink
- The first anti-hangover drink in Korea
1986
Launched HEPACCINE-B, Hepatitis B vaccine
- first-developed in Korea
- World's 2nd hepatitis B vaccine HEPACCINE-B, obtained WHO certification (1993)